Brief: Bioxyne Posts A$7.2 Mln Q3 Revenue
28/04/2025 02:53
April 28 (Reuters) - Bioxyne Ltd BXN.AX: A$7.2 MILLION Q3 REVENUE] Further company coverage: BXN.AX ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on BLS Pharmaceuticals
See all newsBrief: Bioxyne Secures A$50M Exclusive German Supply Agreement With Adrex
Australia's Bioxyne rises to near 8-year high after company secures German supply deal
Australia's Bioxyne at two-week high on supply deal with Remidose LATAM
Brief: Bioxyne Expands LATAM Footprint First Supply Agreement Costa Rica
Australia's Bioxyne hits nearly 8-year high on cannabis firm deal